CMB · ASX

Cambium Bio Ltd (ASX:CMB)

AU$0.23

 0.01 (4.545%)
ASX:Live
13/06/2025 03:34:14 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CMB Overview

CMB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About CMB

Website

N/A

Telephone

61.13.0099.5098

Address

Unit 2.06 31 Lexington Drive Bella Vista, New South Wales (NSW) 2153

Description

Cambium Bio Ltd. engages in the development and commercialization of regenerative therapies derived from novel processed human platelets. The company is headquartered in Paddington, Australia.

CMB Price Chart

Key Stats

Market Cap

AU$4.02M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.19 - 0.68

Trade Value (12mth)

AU$635.00

1 week

-4.17%

1 month

21.05%

YTD

-45.88%

1 year

-61.67%

All time high

64.51

Key Fundamentals

EPS 3 yr Growth

-158.10%

EBITDA Margin

%

Operating Cashflow

$0m

Free Cash Flow Return

-10.00%

ROIC

-144.60%

Interest Coverage

-6.50

Quick Ratio

1.30

Other Data

Shares on Issue (Fully Dilluted)

12m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CMB Announcements

Latest Announcements

Date Announcements

23 May 25

Change of Address

×

Change of Address

22 May 25

Initial Director's Interest Notice - Denese Marks

×

Initial Director's Interest Notice - Denese Marks

22 May 25

Final Director's Interest Notice - Barry Sechos

×

Final Director's Interest Notice - Barry Sechos

21 May 25

Board and Company Secretary Changes

×

Board and Company Secretary Changes

28 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

14 April 25

Change of registry address

×

Change of registry address

11 April 25

Notice of ceasing to be a substantial holder

×

Notice of ceasing to be a substantial holder

21 March 25

Cambium Bio - Release of Shares from Escrow

×

Cambium Bio - Release of Shares from Escrow

18 March 25

Notice of change of interests of substantial holder-CMB

×

Notice of change of interests of substantial holder-CMB

18 March 25

FDA Approves Cambium Bio's Potency Assay Strategy for Elate

×

FDA Approves Cambium Bio's Potency Assay Strategy for Elate

12 March 25

Change of Directors Interest Notice

×

Change of Directors Interest Notice

12 March 25

Notification regarding unquoted securities - CMB

×

Notification regarding unquoted securities - CMB

12 March 25

Application for quotation of securities - CMB

×

Application for quotation of securities - CMB

07 March 25

Mr Chiu - Director Appointment and Appedix 3X

×

Mr Chiu - Director Appointment and Appedix 3X

04 March 25

Results of General Meeting

×

Results of General Meeting

03 March 25

Response to queries re Appendices 3X and 3Z

×

Response to queries re Appendices 3X and 3Z

28 February 25

Update - Proposed issue of securities - CMB

×

Update - Proposed issue of securities - CMB

27 February 25

Half Year Report and Accounts

×

Half Year Report and Accounts

25 February 25

FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol

×

FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol

17 February 25

Final Director Interest Notice-Graham Vesey

×

Final Director Interest Notice-Graham Vesey

17 February 25

Initial and Final Director Interest Notices-Chandra Bala

×

Initial and Final Director Interest Notices-Chandra Bala

13 February 25

Placement Shares Cleansing Notice

×

Placement Shares Cleansing Notice

13 February 25

Application for quotation of securities - CMB

×

Application for quotation of securities - CMB

31 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 January 25

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

CMB Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -1.41 -0.55 -0.54 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -1.41 -0.55 -0.54 Lock Lock Lock
     Growth % Lock Lock Lock Lock -251.5 61.0 1.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.98 -0.34 -0.18 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -1.18 -0.22 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -213.3 65.5 47.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -19.3 -30.8 -7.5 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.35 -0.04 0.23 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.35 -0.04 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -74.3 -111.6 167.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 3 3 4 Lock Lock Lock
Basic m Lock Lock Lock Lock 3 3 4 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.0 N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 5 2 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 74.3 1,342.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 61.8 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 38 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -5 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -373.7 51.5 21.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -1,359.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -5 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -384.3 51.6 22.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -1,360.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -5 -3 -2 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -4 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -256.2 60.9 -33.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -1,748.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -1 0 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 1 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -1 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -249.3 81.7 76.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -1.2 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 0 0 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 3 2 6 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 1 0 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 3 Lock Lock Lock
Equity $m Lock Lock Lock Lock 1 0 3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 1 0 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -74.1 -111.6 2,696.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -168.7 -68.4 -39.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -401.0 1,350.0 -81.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -149.0 -195.1 -101.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -164.8 -354.3 -144.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -137.3 -138.7 -10.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -63.7 -6.4 -6.5 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.2 -0.0 1.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 85.0 -35.4 -86.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.5 1.0 1.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.5 1.0 1.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 12.1 12.3 89.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -243.2 -25.5 -6.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 946.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 -1,785.9 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 -40.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -168.7 -68.4 -39.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.4 -19.7 2.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -401.0 1,350.0 -81.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -401.0 1,350.0 -81.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 945.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 945.1 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 7,525.8 11,774.2 5,472.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -7,525.8 -11,774.2 -4,527.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CMB Shortsell

Frequently Asked Questions

The current share price of Cambium Bio Ltd (CMB:ASX) is AU$0.23.
The 52-week high share price for Cambium Bio Ltd (CMB:ASX) is AU$0.68.
The 52-week low share price for Cambium Bio Ltd (CMB:ASX)? is AU$0.19.
Cambium Bio Ltd (CMB:ASX) does not pay a dividend.
Cambium Bio Ltd (CMB:ASX) does not pay a dividend.
Cambium Bio Ltd (CMB:ASX) has a franking level of 0.0%.
Cambium Bio Ltd (CMB:ASX) is classified in the Healthcare.
The current P/E ratio for Cambium Bio Ltd (CMB:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.